Insight 2: Tepotinib Plus Osimertinib In Egfr-Mutant Nsclc With Resistance To 1st-Line Osimertinib Due To Met Amplification
JOURNAL OF THORACIC ONCOLOGY（2021）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined